Learning hub

The iPROLEPSIS project is where psoriatic arthritis inflammation is explained through multi-source data analysis guiding a novel personalized digital care ecosystem. iPROLEPSIS is een oplossing voor artritis psoriatica Het iPROLEPSIS-project richt zich op het uitleggen van artritis psoriatica door gebruik te maken van data-analyse uit verschillende bronnen. Het project zal leiden tot een nieuw, gepersonaliseerd digitaal zorg-ecosysteem. OVER HET CONSORTIUM NEEM CONTACT MET ONS OP maart 2026 Vandaag ma di wo do vr za zo 23 24 25 26 27 28 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 1 2 3 4 5 Aankomende evenementen Artritis psoriatica (PsA) is een chronische progressieve ontstekings ziekte die 1-2% van de algemene bevolking treft, en zich ontwikkelt bij tot wel 30% van de mensen met psoriasis (PsO). Projectvisie en impact Het iPROLEPSIS-project, gefinancierd door Horizon Europe, heeft als doel een nieuw gepersonaliseerd digitaal zorgecosysteem te ontwikkelen voor mensen met artritis psoriatica (PsA). Het doel van iPROLEPSIS is om een nieuw ecosysteem te ontwikkelen waarin mechanismen voor het verzamelen van Real World Data (RWD) en een krachtig beslissingsondersteunend systeem geïntegreerd zijn. Dit ecosysteem zal nieuwe inzichten verschaffen in de belangrijkste factoren die de overgang van gezondheid naar PsA beïnvloeden door middel van een multiscale en multifactoriële aanpak. Door gebruik te maken van op xAI gebaseerde modellen streeft iPROLEPSIS naar een efficiënt, effectief en klinisch gevalideerd gepersonaliseerd digitaal zorgsysteem voor patiënten met PsA. ONTDEK MEER Projectdoelstellingen en werkpakketten Het iPROLEPSIS-consortium werkt aan zeven ambitieuze kerndoelstellingen op het gebied van artritis psoriatica (PsA) en omvat zes werkpakketten die de diverse en elkaar aanvullende expertises van de consortiumpartners zullen bundelen. ONTDEK MEER Over het project 15 Partners 9 Landen 48 m Projectduur € 6,4M Totale budget De kernactiviteit domeinen De basis • De onderzoeksactiviteiten van het project zijn gebaseerd op een uitgebreide verkenning van de beschikbare literatuur en data, evenals op het ontwerp van klinische dataverzamelings- en validatiestudies; • Een participatief ontwerp zal worden toegepast om de ontwikkeling van een gebruikersgericht ecosysteem van oplossingen te ondersteunen. Dit zal bijdragen aan het opzetten van een betrouwbaar kader voor AI-gebaseerd onderzoek en ontwikkeling. Validatie • Het ontwerpen en implementeren van klinische studies die onderzoeksgegevens verzamelen, digitale biomarkers voor ontstekingssymptomen valideren bij personen met een risico op PsA en patiënten met psoriasis (PSO), en de effectiviteit van digitale zorginstrumenten evalueren met betrekking tot de preventie van ontstekingsuitbarstingen. Onderzoek en ontwikkeling • Het onderzoek richt zich op multimodale gegevens om de belangrijkste oorzaken van PsA-ontsteking te identificeren, digitale biomarkers voor PsA-ontstekingssymptomen te ontwikkelen, en het effect van PsA op de gewrichten en de microvasculatuur van de huid te onderzoeken, evenals de rol van mestcellen bij de overgang naar PsA; • De uitkomsten samenbrengen in een multischaal/multifactorieel model van de transitie van gezondheid naar PsA; • Het leveren van een geïntegreerd iPROLEPSIS digitaal gezondheidszorgecosysteem, bestaande uit tools voor gepersonaliseerde preventieve PsA-zorg, om patiënten en zorgverleners te versterken. Learning Hub Explore resources to help you understand and manage psoriatic arthritis. Handbook Handbook 2 Psoriatic Arthritis Key Facts Key Facts Psoriatic Arthritis Handbook Handbook Quizzes about Psoriatic Arthritis Take a Quiz Project news Handbook Handbook 2 iPROLEPSIS Newsletter No. 11 Read More AI-Driven Early Prediction and Personalised Care | iPROLEPSIS, AI-PROGNOSIS & REBECCA Read More Modeling Interphalangeal Joints for Swelling Assessment in Psoriatic Arthritis via Smartphone Photographs Read More ONTDEK MEER Neem contact op Wij staan open voor uw opmerkingen of vragen over het iPROLEPSIS-project! NEEM CONTACT MET ONS OP

Over onze consortium partners Kristina Leipuviene SmartSol SIA Position Project manager What is your role in iPROLEPSIS? Dissemination/Communication lead What are your main activities in the project? Leading and planning communication and dissemination activities. SmartSol team also supports networking and clustering with stakeholders. What is your motivation? As leaders of WP6, SmartSol aims to increase awareness of iPROLEPSIS and make it accessible to everyone. We focus on sharing information, raising awareness about psoriatic arthritis, and making a lasting impact through thoughtful planning and engagement with the public. Coordination Clinical Experts Data Science Software Development Ethics, Legal and Exploitation Dissemination and Communication

Download needed deliverables for iProlepsis project for psoriatic arthritis. Resultaten D1.2 Data managmeent plan (initial version) WP1 - Management and coordination Read More D2.3 The iPROLEPSIS trustworthy AI framework WP2 - Knowledge mining, foundation and participatory design Read More D6.1 Project branding and communication channels WP6 - Dissemination, communication and exploitation Read More D2.1 Initial report on user research and co-creation process WP2 - Knowledge mining, foundation and participatory design Read More D4.2 The iPROLEPSIS patient and HCP apps (study version) WP4 - Development of the iPROLEPSIS digital health ecosystem for personalised preventive care Read More D6.2 Dissemination, exploitation and communication plan WP6 - Dissemination, communication and exploitation Read More D2.2 Initial report on the state-of-the-art and datasets WP2 - Knowledge mining, foundation and participatory design Read More D5.1 Study initiation package (iPROLEPSIS-PDPID study) WP5 - Clinical studies Read More D6.3 First report on project visibility and educational material WP6 - Dissemination, communication and exploitation Read More

Learning how to live with psoriatic arthritis might feel like a challenge. But understanding your diagnosis can help you take control of your health. Learning hub Explore resources to help you understand and manage psoriatic arthritis. Learning hub Key Facts Handbook News Feed Quizzes Search Psoriatic Arthritis Handbook Living with Psoriatic Arthritis Handbook How will psoriatic arthritis affect me? WORK Work can provide a sense of purpose, identity, achievement, and a supportive social network, contributing positively to your emotional and physical wellbeing. While your condition may pose some challenges, people living with psoriatic arthritis can continue to work as long as their profession does not exacerbate their symptoms and worsen their health. People with certain health conditions have defined rights set out in law, designed to protect them against direct and indirect discrimination in the workplace. Your employer is legally obligated to make “reasonable accommodations” to your working environment and practices to ensure your condition does not prevent you from doing your job to the best of your ability and in a comfortable and safe environment. h3.1 In the European Union, the definition of reasonable accommodation at work was introduced by Article 5 of the Employment Equality Directive (Directive 2000/28/EC): “shall take appropriate measures, where needed in a particular case, to enable a person with disability to have access to, participate in, or advance in employment, or to undergo training, unless such measures would impose a disproportionate burden on the employer.” This directive has been transposed into national law in all EU member states. Research has shown that people who need workplace accommodations and effectively use them are more likely to keep a job and stay productive than those who do not use workplace accommodations (39). However, asking for workplace accommodations can be difficult. You may be concerned about being treated differently and negative reactions from your supervisor(s) or colleague(s). For this reason, you may prefer to negotiate informal workplace accommodations rather than seeking formal accommodations. Some of these accommodations may include those supported by the American College of Sports Medicine guidelines for physical activity and public health (40) and the ISO 11226 standard , https://www. iso.org/standard/25573.html , which defines joint limits to safeguard musculoskeletal health. By aligning workplace practices with these scientifically supported guidelines, employers and healthcare professionals can better accommodate the needs of their employees, fostering an inclusive and supportive work environment. Some examples follow: Recommendation #1: Avoid working for prolonged periods in the same position, whether sitting or standing. During the work shift: a continuous period of time in the standing position should not exceed 1 hour; the total time spent in a standing position should not exceed 4 hours; continuous sitting should be limited to 2 hours; when periods are dedicated to holding meetings, the duration of which should be reasonable, consideration should be given to the possibility of having them while standing or walking (41). Recommendation #2: Take frequent breaks throughout the shift. Please note that he definition of “breaks” must consider the following characteristics: Frequency: number of breaks/interruptions during the working day; Duration: micro-breaks (less than 2 minutes); short breaks (typically those that occur in the morning or afternoon, lasting between 7 and 10 minutes); or long breaks (meal breaks); and Type: passive or resting and active (including stretching or walking) (42). Thus, in an 8-hour working day, a worker should take at least a 7–10-minute break after consecutive 90-minute work periods. Recovery periods can include moments of rest or the performance of any other task to recover the muscle groups that have been worked. Within a period of at least 90 minutes, a worker should enjoy at least 30 seconds after 20 minutes of work. Both recommendations aim to address the prolonged exposure to low-intensity static load by limiting the duration of this exposure. These interventions help to alleviate fatigue and pain symptoms in the short-term, and to prevent work-related musculoskeletal injuries in the long-term. Active breaks add value; however, they do not replace the need to introduce diversity in the intensity of the mechanical load, such as rotational planes suited to the job’s demands (43). Please note that these recommendations refer to low-intensity, physically demanding tasks. Other recommendations apply to high-intensity tasks, such as those involving manual force. Recommendation #3: Physical changes to workstations work surfaces (desks) that allow alternation between standing and sitting, alone or combined with a training and information program for workers, reduce sitting time by approximately 60 minutes per working day (in the medium term, i.e., up to 3-12 months). This change in physical working conditions can bring about a behavioural change, with repercussions in an average reduction of 82 minutes in total sitting time per day (at and away from work) and in the average duration of consecutive periods of sitting (57 minutes) (42, 44). Even though workplace adaptations are consigned in the law, many people living with rheumatic and musculoskeletal diseases report a lack of understanding from their employer(s), colleague(s), and workplace doctor(s). You have options and rights; it is important to understand them and fully explore all available alternatives. If you are unsure about your rights in the workplace, please get in touch with your HR or occupational health department. More information can be found below: The Advisory, Conciliation and Arbitration Service. (ACAS) https://www.acas.org.uk/reasonable-adjustments If you require workplace adaptations, please talk to your assistant doctor about the difficulties you have been feeling and request reports to present to your employer and/or workplace doctor. See related Key Facts section SLEEP Pain, anxiety, and side effects of the medication can make it more difficult for a person with psoriatic arthritis to fall asleep and stay asleep throughout the night. In fact, about 40% of people living with psoriatic arthritis report sleep difficulties (45). Good sleep hygiene habits may help to improve sleep: develop a regular sleep routine, that is, go to bed and get up at a similar time each day; avoid caffeine, alcohol, and large meals before you go to bed; if you smoke, try to stop smoking, or at least do not smoke close to bedtime; a warm bath before bedtime may help ease pain and stiffness; listen to soothing music or sounds before going to bed; avoid watching TV and using computers, tablets, or smartphones in your bedroom; make sure your bedroom is dark, quiet, relaxing, and at a comfortable temperature. h3.2 The impact of exercising before bedtime can vary among individuals. It is essential to listen to your body, establish a consistent routine, and pay attention to how evening workouts affect your sleep patterns. If you have specific concerns about your sleep or exercise routine, it is also advisable to consult with a healthcare professional or a fitness expert. Pros: Improved sleep quality: For some people, engaging in moderate-intensity exercises a few hours before bedtime may promote better sleep quality. It can help reduce stress and anxiety, leading to a more relaxed state conducive to sleep. Body temperature regulation: Exercise increases body temperature, and the subsequent drop in temperature after exercise can signal the body that it is time to sleep. This mimics the natural temperature drop that occurs during the evening. Establishing a routine: Regular exercise, regardless of the time of day, can contribute to better sleep quality. Establishing a consistent exercise routine is often more important than the specific time of day. Cons: Stimulating effect: For some people, intense exercise close to bedtime may have a stimulating effect, making it more challenging to wind down and fall asleep. Body temperature: While the drop in body temperature after exercise can promote sleep, exercising too close to bedtime may disrupt the body’s natural cooling process, potentially interfering with sleep. Individual variability: People respond differently to exercise timing. Some may find that late-night workouts do not impact their sleep, while others may experience difficulties. Recommendations: Timing matters: Try to finish exercising at least 2-3 hours before bedtime to allow your body temperature to return to normal and your adrenaline levels to decrease. Listen to your body: Pay attention to how your body responds to evening workouts. It might be a good fit for you if it helps you relax and improves your sleep. Experiment: Everyone is different. Experiment with varying timings of exercise to see what works best for you. If evening workouts negatively impact your sleep, consider shifting them earlier. Moderation is key: Intense or vigorous exercise close to bedtime might be more likely to interfere with sleep. Opt for moderate-intensity activities in the evening (47). Nearly 50% of patients living with psoriatic arthritis report high levels of fatigue (five or higher on a 10-point scale) and consider fatigue a high-ranking problem, after joint pain and before skin issues (48). See related Key Facts section FATIGUE Problem solving, planning, prioritising, and pacing may help you cope better with your fatigue: PROBLEM SOLVING Identify factors / tasks / chores / activities that are contributing to your fatigue; Think about solutions that could help minimise the impact of these factors/tasks/chores/ activities. PLANNING Plan the tasks/chores/activities you want to complete in a day or week; Make sure to include activities that you enjoy and can improve your mood/wellbeing; Do not beat yourself up if you cannot stick to the plan. PRIORITISING Organise your tasks/chores/activities by order of importance. PACING Do not use your energy all in one go; Break the planned tasks/chores/activities into smaller portions that can be spread out over the course of a day, a week or even longer. See related Key Facts section EMOTIONAL WELLBEING Living with psoriatic arthritis can take a toll on your mental health (49, 50). You need to treat mental health symptoms as seriously as physical symptoms. Poor mental health can cause your psoriatic arthritis to flare, increase pain and fatigue, negatively affect your work and personal relationships, and limit your ability to manage your overall health. If you feel sad, hopeless, and lose interest in things you used to enjoy, talk to your doctor, and let your loved ones know what you are going through. Your doctor may redirect you to useful mental health services such as cognitive behavioural therapy (CBT) and/or they may prescribe you an antidepressant. h3.3 h3.4 Remember that you are not alone. If you need extra support, we are here to help you: NHS Mental Health Services https://www.nhs.uk/nhs-services/mental-health-services/ VERSUS ARTHRITIS / Psoriatic arthritis https://versusarthritis.org/ +44 800 520 0520 Be kind to your joints and your mind. See related Key Facts section See related Key Facts Previous page Next page

iPROLEPSIS project will perform four different clinical studies in four different counties. Learn more about clinical studies by visiting iprolepsis.eu. Over de klinische studies iPROLEPSIS zal vier verschillende klinische studies uitvoeren: 1. iPROLEPSIS-PDPID Onderzoek naar digitale fenotypering van PsA en factoren die ontstekingen veroorzaken. 2. iPROLEPSIS-MOJMI Studie naar mestcellen en door opto-akoestiek ondersteunde gewrichts- en microvasculaire beeldvorming. 3. iPROLEPSIS-IDBV Validatieonderzoek van digitale biomarkers voor ontstekingen. 4. iPROLEPSIS-PPIDC Onderzoek naar de preventie van PsA-ontstekingen via digitale zorginterventies. Klinische onderzoeken zullen worden uitgevoerd in vijf landen: Nederland Groot-Brittannië Portugal Griekenland Duitsland Klinische studies PsA onderzoek naar digitale fenotypering en ontstekingsfactoren (iPROLEPSIS-PDPID) Een ontwikkelingscohort voor AI-gestuurde digitale biomarkers, gebaseerd op smartphones en smartwatches, voor de beoordeling en monitoring van mensen met artritis psoriatica op afstand. Meetmaat Het ontwikkelen van nieuwe digitale biomarkers, met behulp van smartphones en smart device (riem, ring, camera) gegevens, om ontstekingssymptomen te beoordelen. Speciale aandacht gaat uit naar het herkennen van veranderingen in bewegingspatronen, pijn, vermoeidheid en ochtendstijfheid, vergeleken met de medische gouden standaard - de klinische evaluatie van gewrichten, pezen en huid. Voorspellen Het voorspellen van de overgang van niet-ontstoken naar ontstoken toestanden bij patiënten met artritis psoriatica die risico lopen op opvlammingen, door gebruik te maken van drie triggers: stress, mechanische stress en veranderingen in het darmmicrobioom. DOELSTELLINGEN Primaire doelstellingen • Het verschaffen van nauwkeurige, feitelijke en klinisch relevante gegevens over het op smartphones en smartwatches gebaseerde, AI-aangedreven digitale biomarkersysteem bij de detectie van PsA-specifieke ontstekingen; • Het voorspellen van nauwkeurige, feitelijke en klinisch relevante PsA-specifieke ontstekingen. Secundaire doelstellingen • Het bepalen van de interpersoonlijke betrouwbaarheid van het AI-gestuurde digitale biomarkersysteem; • Het bepalen van de constructvaliditeit ten opzichte van de klinische beoordeling van ontstekingen; • Het bepalen van de constructvaliditeit ten opzichte van de beoordeling van ontsteking door de patiënt; • Het bepalen van klinisch relevante veranderingen in het AI-gestuurde digitale biomarkersysteem; • Het bepalen van het minimaal detecteerbare verschil in het AI-aangedreven digitale biomarkersysteem; • Het beoordelen van de interpersoonlijke variatie van stress, mechanische stress en veranderingen in het darmmicrobioom op het optreden van ontstekingen; • Het evalueren van de naleving en tevredenheid van de gebruikers met het op smartphones en smartwatches gebaseerde, AI-gestuurde digitale monitoringsysteem. De studie is bedoeld om een nieuwe manier te ontwikkelen om ontstekingen te meten bij patiënten met artritis psoriatica. Definitie van nieuwe opto-akoestische biomarkers van psoriasis en artritis psoriatica (iPROLEPSIS-MOJMI) Het onderzoek naar mestcellen en opto-akoestische gewrichts- en microvasculaire beeldvorming (iPROLEPSIS-MOJMI) maakt gebruik van een multischaalaanpak (mesoscopisch met RSOM en macroscopisch met MSOT) om nieuwe, op beelden gebaseerde biomarkers te verkennen. Het doel is om de pathofysiologische veranderingen die PsO karakteriseren te beschrijven en de overgang naar PsA te voorspellen door middel van microvasculaire beeldvorming van de huid. Met andere woorden, het unieke multischaalkarakter van opto-akoestiek van de microvasculatuur van de huid zal naar verwachting inzicht geven op latere systemische (gewrichts)effecten van psoriasis en zo de prognose verbeteren bij toekomstige patiënten met PsO. DOELSTELLINGEN Primaire doelstellingen • Het definiëren van nieuwe inflammatoire mestcellen en het extraheren van MSOT- en RSOM-biomarkers bij patiënten met PsO/PsA. • Het kwantificeren van veranderingen in nieuwe inflammatoire mestcellen door middel van MSOT- en RSOM-geëxtraheerde biomarkers bij toenemende ernst van de ziekte. Secundaire doelstellingen • Het onthullen van correlaties tussen mestcellen en MSOT- en RSOM-geëxtraheerde inflammatoire biomarkers bij patiënten met PsO/PsA. • Het definiëren van een nieuwe index afgeleid van mestcellen en MSOT- en RSOM-gebaseerde kenmerken om vroege detectie van PsA mogelijk te maken bij patiënten met PsO of een hoog risico op het ontwikkelen van PsO. Validatiestudie digitale biomarkers voor ontstekingen (iPROLEPSIS-IDBV) Het identificeren van individuen die de overgang van gezondheid naar ontsteking zullen maken, is een uitdagende taak bij immuungemedieerde ontstekingsziekten (IMID). De eerste symptomen zijn vaak vergelijkbaar met die van andere musculoskeletale aandoeningen, zoals rugpijn, pijn in de vingers of problemen met de achillespees. Na verloop van tijd kunnen deze symptomen tijdelijk verdwijnen, chronisch worden, of zo ernstig worden dat medische interventie noodzakelijk is. Vroegtijdige identificatie van mensen met IMID zou aanzienlijke voordelen opleveren voor hun kwaliteit van leven, hen in staat stellen om actief te blijven werken, en dure gezondheidszorgkosten vermijden door preventieve maatregelen. Digitale biomarkers bieden nu voor het eerst de mogelijkheid om de overgang van musculoskeletale aandoeningen naar immuungemedieerde inflammatoire gewrichts- en peesaandoeningen te bestuderen. Het doel van deze studie is om onze bevindingen over digitale biomarkers bij psoriasispatiënten met PsA te valideren. DOELSTELLINGEN Primaire doelstellingen • Het valideren van nauwkeurige, feitelijke en klinisch relevante gegevens van het op zichzelf staande smartphone- en smartwatch-gebaseerde, AI-aangedreven digitale biomarkersysteem bij de detectie van IMID-specifieke gewrichts- of peesontsteking. Secundaire doelstellingen • Het evalueren van de acceptatie en aanvaardbaarheid van de digitale biomarker in het dagelijks leven; • Het beoordelen van de impact van ontbrekende gegevens bij het detecteren van ontstekingen; • Het evalueren van het aantal vals-positieven bij het vastleggen van gegevens in het dagelijks leven; • Het beoordelen van de interpersoonlijke variatie van stress en mechanische stress. Het doel is om ontstekingen te identificeren met behulp van een op software gebaseerd medisch apparaat. Deze software zal een algoritme omvatten dat gegevens analyseert die in het dagelijks leven zijn verzameld via slimme apparaten zoals telefoons, horloges en ringen. Preventie van PsA-ontsteking door digitale zorg: een interventiestudie (iPROLEPSIS-PPIDC) Deze studie integreert de bevindingen van nieuw ontwikkelde digitale biomarkers en vroege triggers zoals stress, mechanische stress en veranderingen in het microbioom uit het onderzoek naar digitale fenotypering en ontstekingsfactoren van PsA (iPROLEPSIS-PDPID), om een gepersonaliseerde aanpak te ontwikkelen voor het beheer van deze triggers met state-of-the-art interventies. DOELSTELLINGEN Primaire doelstellingen Het vergelijken van een gepersonaliseerde interventie op het gebied van voeding, fysieke activiteit en stress bij PsA-patiënten met lage ziekteactiviteit, gebaseerd op een persoonlijk profiel van stress, mechanische stress en microbioom, met de gebruikelijke zorg voor de ontwikkeling van ontstekingen zoals gedetecteerd door het nieuw ontwikkelde digitale biomarkersysteem en klinische beoordeling. Secundaire doelstellingen • Het evalueren van de acceptatie en aanvaardbaarheid van de digitale biomarker en de gepersonaliseerde interventie als onderdeel van normale medische behandelingen onder patiënten, artsen en verpleegkundigen; • Het beoordelen van het gebruik van de gepersonaliseerde interventie.

Learning how to live with psoriatic arthritis might feel like a challenge. But understanding your diagnosis can help you take control of your health. Learning hub Explore resources to help you understand and manage psoriatic arthritis. Learning hub Key Facts Handbook News Feed Quizzes Search Psoriatic Arthritis Key Facts Key Facts Quizzes about Psoriatic Arthritis Take a Quiz Search about Psoriatic Arthritis Search Psoriatic Arthritis Handbook Handbook News Feed about Psoriatic Arthritis News Feed

Over onze consortium partners Vasilis Charisis Signal Processing & Biomedical Technology Unit (SPBTU) – Aristotle University of Thessaloniki Position Principal researcher focusing on the development of digital biomarkers and their translation into healthcare tools and interventions. What is your role in iPROLEPSIS? Scientific and Technical Coordinator. What are your main activities in the project? I manage the project's day-to-day operations and scientific coherence, driving the timely delivery of outcomes. Our team (SPBTU) is pioneering the use of AI and digital biomarkers from everyday smart devices to create predictive models for PsA symptoms. We are also developing a dedicated mobile app that supports patients by improving sleep patterns using binaural beat technology. What is your motivation? My motivation is rooted in a long-standing commitment to improving chronic disease management through accessible, non-invasive technology. In iPROLEPSIS, I am driven to apply advanced AI and biomedical engineering principles to address the significant challenges faced by PsA patients. We aim to create tangible, personalized digital tools that not only predict disease flares early but actively enhance patients' quality of life, ensuring our cutting-edge research delivers real clinical benefits. Coordination Clinical Experts Data Science Software Development Ethics, Legal and Exploitation Dissemination and Communication

Welcome to our collaborative initiative, a dedicated networking subpage showcasing the synergistic efforts of innovative projects. iPROLEPSIS networking activities Our shared vision is to establish a robust ecosystem of initiatives , where the combined strength of each project contributes to the overarching goal of advancing healthcare and well-being . By pooling our resources, knowledge, and expertise, we believe in the potential for significant benefits both for the collaborative cluster and the individual projects involved. Networking projects funded under the call HORIZON-HLTH-2022-STAYHLTH-02-01 CARE-IN-HEALTH Cardiovascular REsolution of INflammation to promote HEALTH WEBSITE Cardiovascular diseases (CVD) are the leading cause of mortality in Europe (1.9 million of annual deaths). CVD are significant public health challenge, accounting for €200 billion in economic burden annually in Europe. Lipid-mediated chronic inflammation and particularly the failure in the resolution of the inflammation, is a particular critical risk factor for the transition from health to CVD. CARE-IN-HEALTH addresses this by aiming to identify the pathways involved in the resolution of the lipid-mediated inflammation to prevent and reverse inflammation and therefore CVD. The interdisciplinary consortium will collect and integrate epidemiological, multi-omics, and immune data to create the CARE-IN-HEALTH Atlas, which will be openly accessible to the scientific community. Such a knowledge base will allow to systematically identify and validate individual’s critical immune pathways. A CARE-IN-HEALTH MCDSS (multi-criteria decision support system) will guide healthcare professionals to design personalised CVD prevention strategies. The CARE-IN-HEALTH BIOSENSOR will monitor inflammation resolution for citizens. CARE-IN-HEALTH will demonstrate proof-of-concept for an appropriate lipid intake as dietary intervention and specifically, for the use of vegetal omega-3 fatty acid sources as substrates for immunomodulatory lipid mediators and resolution of inflammation. All this is based on the results of a proof-of-concept clinical trial. GlycanTrigger Glycans as master triggers of health to intestinal inflammation transition WEBSITE GLYCANTRIGGER - Glycans as master triggers of health to intestinal inflammation transition. The GlycanTrigger project proposes a thorough and innovative approach to understand better the health-to-chronic inflammation transition occurring in patients with Crohn’s Disease that will be translated into improved disease prediction and prevention. The project will address how changes in glycosylation of the gut mucosa act as a primary event that dysregulates not only local mechanisms but also systemic mechanisms, involving the novel concept of glycan mimicry as an early trigger of the health-to-inflammation transition. The long-term goal of this project is to unlock a new checkpoint that regulates the transition to chronic inflammation, aiming to figure out how to turn off this process by developing novel preventive intervention strategies. halt-RONIN Discovering chronic inflammation biomarkers that define key stages in the Healthy-to-NASH (non-alcoholic steatohepatitis) transition to inform early prevention and treatment strategies. Downolad PDF to read more. WEBSITE NAFL (non-alcoholic fatty liver) is the most widespread subtype of NAFLD, a highly prevalent inflammation-related disease, characterized by steatosis, relatively benign and reversible condition, which can progress to the more serious progressive stage of non-alcoholic steatohepatitis (NASH), in which steatosis is accompained by lipotoxicity, mitochondrial dysfunction and a high state of inflammation and fibrosis. IMMEDIATE Imminent Disease Prediction and Prevention at the Environment Host Interface WEBSITE The EU-funded research project IMMEDIATE strives to identify individual biomarkers of risk and resilience against chronic inflammation by investigating the diet-microbiome-metabolite-immune axis. This complex interaction refers to how an individual's diet, gut microbiota, metabolites, and immune system can influence their health. IMMEDIATE will use cutting-edge technologies and clinical and metadata from large observational cohort studies to identify pre-disease stages and further our understanding of the mechanisms and molecular pathways underpinning non-communicable diseases. Furthermore, a proof-of-concept study on healthcare professionals will be conducted to test the effectiveness of a probiotic intervention and ultimately develop mobile apps designed to offer personalized lifestyle recommendations and empower citizens to manage their own health proactively. INITIALISE Inflammation in human early life: targeting impacts on life-course health WEBSITE INITIALISE (Inflammation in human early life: targeting impacts on life-course health) is an EU funded project that aims to elucidate how exposures and genome impact gut microbiome, host immune system and metabolism, and how the interplay of these factors impact life-course health.  INITIALISE aims to define the role of the maturation of the immune system as a mediator between exposures and life-course health. INTERCEPT-T2D Early Interception of Inflammatory-mediated Type 2 Diabetes WEBSITE Inflammatory-based interceptive medicine in type 2 diabetes Individuals with type 2 diabetes (T2D) do not use insulin efficiently and, therefore, their glucose levels rise. T2D is a heterogeneous disease, which is an obstacle to the delivery of an optimal tailored treatment. Consequently, patients’ individual trajectories of progressive hyperglycaemia and risk of chronic complications such as stroke, heart attacks, nephropathy and retinopathy are so far difficult to predict. Chronic systemic inflammation has been suggested to be a major contributor to the onset and progression of T2D complications. The EU-funded INTERCEPT-T2D project will bring a new and clinically relevant dimension in T2D care considering at diagnosis inflammatory parameters that are of importance for the transition to T2D-related complications. Moreover, the project will help deliver optimal treatments tailored to patient needs and conduct a clinical trial to evaluate the efficacy of anti-inflammatory strategies. miGut-Health Personalised blueprint intestinal health WEBSITE The miGut-Health project is an EU-funded initiative that is developing novel strategies to predict and prevent inflammatory bowel disease (IBD). miGut-Health aims to create personalised patient engagement strategies for predicting and monitoring preclinical IBD by focusing on the transitory phase from health to disease. The overarching goal is to provide strategies for early disease prediction, prevention and gut health improvement for people affected by IBD, high-risk individuals and citizens. AIDA An Artificially Intelligent Diagnostic Assistant for gastric inflammation WEBSITE Most cases of gastric cancer (GC) are detected at a late stage, when patients have a median life expectancy of about a year. Diagnosing people at risk of developing GC at the pre-symptomatic stage, typically chronic gastric inflammation, could significantly improve the outlook. Artificial intelligence (AI) can help clinicians make sense of their own data by automating much of the treatment and analysis, which require manual work and years of experience. But it can do more: it can bring together available data from various sources into a vast data lake and cross-correlate the data to derive a ‘risk score’ for gastric cancer and shed light on the mechanisms of its evolution. Aida aims to do just that. It helps researchers understand the mechanisms that trigger gastric oncogenesis, helps clinicians diagnose precancerous inflammation at the earliest possible stage, suggests personalised therapeutic strategies for treatment and follow-up, and makes personalised recommendations for monitoring patient health status, thus contributing to gastric cancer prevention. This places Aida squarely on Europe’s agenda of ‘Staying healthy in a rapidly changing society’. Aida unites some of Europe’s leading authorities in the field of gastric inflammation, gastric cancer, leading AI and machine learning experts, experts on data governance and privacy, representatives of the public administration and patient advocates. Aida also has strong ties with the industry. After the project, the results will live on in a foundation that acts as a transnational focal point for chronic gastric inflammation — and GC in general. We hope that the solid, inclusive design principles of Aida, its societal relevance and its durability will spawn a vigorous ecosystem around chronic gastric inflammation, its understanding and its treatment. And we hope that it will inspire other data collaboratives in health — for other chronic inflammations, other forms of cancer or other ailments altogether. PROTO Advanced Personalized Therapies for Osteoarthritis WEBSITE Osteoarthritis (OA) is a chronic progressive joint disorder, characterized by inflammation causing pain, stiffness, swelling and gradual loss of joint function. PROTO aims to halt and partially reverse the structural and functional changes caused by inflammatory processes in OA Our ambitious goal is to introduce: a highly innovative anti-inflammatory local placental derived cell therapy in early-stage OA patients and a personalized sensor-based training intervention intended to prevent inflammation and OA onset during a crucially important ‘window of opportunity’ by correcting pathological movement patterns in pre-stage OA patients. ENDOTARGET Sytemic Endotoxemia as the driver of chronic inflammation–Biomarkers and novel therapeutic targets for Arthritis WEBSITE ENDOTARGET explores the relationship between gut microbiota, gut permeability, and systemic endotoxemia with a special focus on the three most abundant rheumatic diseases (RDs): osteoarthritis, rheumatoid arthritis and spondylarthritis. The aim is to clarify (1) the role of the three factors gut microbiota, gut permeability and systemic endotoxemia in RD onset and pathogenesis, (2) which events and mechanisms are responsible for the origin of RDs, and (3) the influence of the gut microbiota on the joints. Based on the gained knowledge, e.g. new biomarkers for risk assessment will be identified and a Rheumatic disease risk prediction tool (RDPT) will be developed to support clinicians in the classification of patients and to treat RDs preventively. This tool will help to reduce the risk of RD onset and/or to reduce disease activity. PRAESIIDIUM Real-time prediction of the prediabetes risk WEBSITE PRAESIIDIUM will develop a tool based on artificial intelligence coupled with multi-scale, multi-organ integrated mathematical equations for the real-time prediction of the prediabetes risk of an individual. The prediction algorithm will draw on a rich set of information for training, derived from prior clinical data, the individual’s family history, and a pilot study testing wearable sensors that will provide glucose, bioimpedance, and heart rate monitoring. The PRAESIIDIUM platform will be made available to healthcare professionals and patients for an easier data entering and results query and it will be linked to common wearable sensors to monitor the physical activity. PREVALUNG EU Biomarkers affecting the transition from cardiovascular disease to lung cancer: towards stratified interception WEBSITE The project PREVALUNG EU will harness retrospective and prospective cohorts of both CVD patients and LCDT eligibles to develop actionable biomarkers and validate the four classifiers detecting high-risk individuals before or pre-symptomatic of LC, exploiting the latest advances of system biology omics (metabolomics, metagenomics, immunomics, proteomics, and aging-associated BM stem cell genomics) that correlate with uncontrolled inflammatory status of CVD patients. In particular, using four types of diagnosis tools harnessing either of the four drivers of overt inflammation (metabolism, gut dysbiosis, stem cell mutational status, innate immunity), we shall stratify the CVD patient population and leverage the PLCOm2012 risk score to better identify LC high-risk individuals. We will propose a personalized interceptive measure, whose efficacy will be monitored using PREVALUNG EU Focus Panels. We will robustly validate clinical applications, workflows, and tools for easy and broad adoption of the interceptive system across European public care centers and private stakeholders.

Over onze consortium partners Dr. Ioannis Drivas DIADIKASIA BUSINESS CONSULTING SYMVOULOI EPICHEIRISEON AE (DBC) Position Principal researcher focusing on the development of digital biomarkers and their translation into healthcare tools and interventions. What is your role in iPROLEPSIS? Project Manager What are your main activities in the project? As Project Manager, I coordinate all iPROLEPSIS-related activities assigned to DBC. What is your motivation? My motivation stems from a strong commitment to upholding ethical and legal standards in research while maximizing the impact and real-world use of the iPROLEPSIS results. Coordination Clinical Experts Data Science Software Development Ethics, Legal and Exploitation Dissemination and Communication

Learning how to live with psoriatic arthritis might feel like a challenge. But understanding your diagnosis can help you take control of your health. Learning hub Explore resources to help you understand and manage psoriatic arthritis. Handbook Learning hub Key Facts Handbook News Feed Quizzes Search Handbook 1 Psoriatic Arthritis Handbook Understanding Psoriatic Arthritis h1.1 What is psoriatic arthritis? Psoriatic arthritis is a type of arthritis linked with psoriasis, a chronic skin and nail disease. Psoriasis causes red, scaly rashes and thick, pitted fingernails. Psoriatic arthritis is characterized by joint swelling (inflammation), pain and stiffness and can affect any peripheral joint such as fingers, toes, knees and/or spine. It also affects the insertion of tendons or ligaments in bones (enthesitis). Between 20-40% of people with the skin condition psoriasis will develop psoriatic arthritis (1, 2). Symptoms affecting their joints tend to develop 5 to 10 years after psoriasis is diagnosed but it can occur at any time (3). Currently, it is not clear why some people with psoriasis develop psoriatic arthritis while others do not. The arthritis of psoriatic arthritis comes in 3 forms: oligoarticular arthritis that affects 4 or less peripheral joints (e.g., joints in the fingers, toes, knees); polyarticular arthritis that involves 5 or more peripheral joints on both sides of the body; and axial arthritis that affects the joints of the spine including the sacroiliac joint (where the spine connects to the pelvis). Some people may develop psoriasis after or at the same time as symptoms of psoriatic arthritis present themselves (4). In rare cases, people may have psoriatic arthritis and never have any noticeable symptoms of psoriasis. Psoriatic arthritis and psoriasis are chronic inflammatory conditions that are caused by a fault in the immune system. Our immune system protects us from infection and illness. See related Key Facts section What causes psoriatic arthritis? While psoriatic arthritis can occur at any age, most people present their first signs and symptoms at 30-50 years. Psoriatic arthritis is most likely to be diagnosed within the first ten years of the psoriasis diagnosis (3). Psoriatic arthritis affects both sexes equally. However, the manifestations in terms of severity and impact of the disease differ between sexes. Men are more likely to have involvement of the bones in the spine (axial arthritis) and radiographic damage in the spine and peripheral joints (e.g., fingers, knees and toes), whereas women are more likely to experience impaired quality of life and severe limitations in function (5). Researchers are not sure why some people develop psoriatic arthritis. It is thought that certain genes inherited from parents and grandparents can make a person more likely to develop psoriatic arthritis (6–8). h1.2 In people with a higher genetic predisposition to develop psoriatic arthritis, the condition can be triggered by environmental factors, such as: an infection (9); an accident or injury (10, 11); being overweight (12); smoking (13, 14). Psoriasis and psoriatic arthritis are not contagious. You cannot catch psoriasis or psoriatic arthritis from other people. See related Key Facts section What are the symptoms of psoriatic arthritis? Psoriatic arthritis symptoms usually develop slowly, that is, many people are unaware that they are developing psoriatic arthritis (Figure 1). Although symptoms can develop suddenly in rarer cases. Some of the main symptoms include (15): pain in one or more joints; swelling in one or more joints; stiffness in one or more joints that lasts for 30 minutes or longer. These symptoms are caused by inflammation and can affect any joint in the body. See Figure 2 for the most commonly affected joints. See related Key Facts section h1.3 Psoriatic arthritis can cause pain and swelling in the entheses, that is, places in the body where tendons and ligaments connect to the bones (15). When the entheses become inflamed it is known as enthesitis. Enthesitis pain can spread along a wider area than joint pain. It frequently occurs at the back of the heel or on the bottom of the foot, which can make standing or walking difficult. Affected areas feel tender to touch even when just a small amount of pressure is applied. The knees, hips, elbows and chest can also be affected by enthesitis. Many people with psoriatic arthritis have swollen fingers or toes, a condition that is known as dactylitis (15) (Figure 1). It most commonly affects one or two fingers or toes at a time. Psoriatic arthritis can also cause small round dents in fingernails and/or toenails, a condition known as pitting. The nails can change colour, become thicker, or even lift away from your finger (15). People living with psoriatic arthritis may feel very tired (fatigued) and some may have a low-grade fever. Fatigue does not get better with rest. Psoriatic arthritis symptoms may come and go. A period of increased inflammation and worsening of other symptoms is called a flare. A flare can last for days or months See related Key Facts section h1.5 How is psoriatic arthritis diagnosed? A timely and accurate diagnosis is an important step for optimising care and improve long-term health outcomes (16). If you have been diagnosed with psoriasis in the past, and symptoms of arthritis (e.g., painful or swollen joints) have started more recently, you may have developed psoriatic arthritis. However, the symptoms of psoriatic arthritis can look like other health conditions. Make sure to see your healthcare provider for a diagnosis. The doctor you see first may depend on whether you have previously been diagnosed with psoriasis. If you develop symptoms of arthritis your primary care or skin doctor should refer you to a rheumatologist – a doctor who specialises in joint conditions – for an assessment. Tell your doctor if you have a history of psoriasis and/or psoriatic arthritis in your family. CURRENTLY, NO SINGLE TEST CAN CONFIRM PSORIATIC ARTHRITIS (15). A diagnosis will be made based on your medical history, symptoms, and a physical examination by your doctor. Your doctor may order X-rays or other types of imaging, such as ultrasound scans and magnetic resonance imaging (MRI), to look for changes to your bones and joints. Imaging studies will help your doctor determine the type and pattern of joint involvement, which can also help them distinguish between arthritis types. Blood tests, such as erythrocyte sedimentation rate and C-reactive protein, can help to identify inflammation. Your doctor may also order tests for rheumatoid factor and the anti-CCP antibody to rule out rheumatoid arthritis and HLA-B types to look for your genetic predisposition to spondylarthritis. See related Key Facts section h1.4 See related Key Facts Previous page Next page

Over onze consortium partners iPROLEPSIS-projectcoördinator Coordination About team Software development About team Clinical experts About team Ethics, legal and exploitation About team Data sience About team Dissemination and communication About team

Over onze consortium partners Francisco Cardoso PLUX Position Software Developer What is your role in iPROLEPSIS? Monitoring Engineer What are your main activities in the project? I define SLIs/SLOs, design telemetry (metrics, logs, traces), build alerts and dashboards, run incident response/postmortems, and align data retention and security with compliance. What is your motivation? I’m motivated by making complex systems trustworthy. Turning real-time signals into fast decisions that reduce downtime and protect participants and data. Hugo Humberto Plácido da Silva PLUX Position Founder & Chief Innovation Officer What is your role in iPROLEPSIS? Principal Investigator representing PLUX. What are your main activities in the project? Internal management of the project at the board/administration level. Our team is making substantial contributions to the development of digital biomarkers (dBMs) that can be acquired using a smart belt. Furthermore, we are responsible for the iPROLEPSIS system orchestration, verification, and monitoring. What is your motivation? Psoriatic Arthritis (PsA) is a highly conditioning disease that currently affects a significant number of patients globally. Existing assessment and management methods are mostly bound to a clinical setting, involving complex protocols, therefore only of limited access to patients. For as long as I can remember, my work has been centered around purpose-driven innovations in the healthcare space; the possibility to explore novel dBMs as a way of improving the lives of PsA patients constitutes a once-in-a-lifetime opportunity and purpose like none other. Sofia Balula Dias Faculdade de Motricidade Humana Position Principal Investigator representing FMH partner What is your role in iPROLEPSIS? As Principal Investigator, I lead the design and development of a serious games-based intervention tool specifically tailored to support individuals living with Psoriatic Arthritis. What are your main activities in the project? Our multidisciplinary team is leading the development of the iPROLEPSIS serious games application to support Psoriatic Arthritis patients. Through co-creation with patients and collaboration across research, clinical, and design fields, we’re tailoring game mechanics and biofeedback features to meet real needs and preferences. Our work involves prototyping, testing, and refining therapeutic content designed to improve mobility, support pain management, reduce stress, and promote self-management, ultimately contributing to a more holistic and patient-centered approach to chronic care. What is your motivation? I am driven by the opportunity to improve the lives of PsA patients through non-pharmacological, technology-driven interventions. Serious games present an innovative and empowering method for symptom management and patient engagement. To date, there are no serious games specifically tailored to the needs of individuals with PsA, making this work both timely and impactful. Rodrigo Duarte Braga PLUX Position Research Collaborator What is your role in iPROLEPSIS? Systems Engineer What are your main activities in the project? I coordinate system orchestration, verification, and monitoring. I also lead the Smartbelt's technical development, from data acquisition and processing device data to building machine learning models. What is your motivation? Tackling complex challenges and developing innovative solutions and medical devices that create tangible value. Sérgio Lopes da Fonseca PLUX Position Project Manager What is your role in iPROLEPSIS? PLUX’s contribution to iPROLEPSIS management. What are your main activities in the project? Aligning timelines, deliverables, and resources across partners. I manage work-package commitments, budget and risks, and represent PLUX in steering and technical meetings to keep decisions action-oriented and on schedule. What is your motivation? To turn research into deployable, user-centred solutions. I’m driven by projects that measurably improve clinical workflows and patient outcomes—while creating a clear path from prototype to scalable product. iPROLEPSIS is a chance to do all three: integrate wearable biosignals seamlessly, prove value in real settings, and accelerate European med-tech competitiveness. Coordination Clinical Experts Data Science Software Development Ethics, Legal and Exploitation Dissemination and Communication